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ABSTRACT
Variables That Affect the Amount of the Consent That 
Clinical Research Subjects Read
by
Joanne Hembree Robinson
Dr. Margaret Louis, Examination Committee Chair 
Professor of Nursing 
University of Nevada, Las Vegas
Various codes, regulations and guidelines have been established that outline what 
information must be provided to human subjects to insure that their participation in 
clinical drug studies is informed as well as voluntary. Recently questions have been 
raised as to whether written consent forms guarantee participants are making 
autonomous, informed decisions. The purpose of this study was to determine how much 
of the consent research subjects read in relation to selected variables. Seventy-seven 
percent of the participants reported that they read the entire consent form, but results 
suggest that 30-40% may not understand the study they are in. A question not answered 
is, do research subjects in clinical drug studies know information pertinent to the study in 
which they are participating.
m
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CHAPTER 1
INTRODUCTION 
Backgound and Significance 
“Any Research Project Utilizing Human Subjects Requires 
the Informed Consent of Those Subjects”
(Federal Regulations Governing Human Experimentation, 46.116)
The Doctrine of Informed Consent was created to protect the rights and welfare of 
human subjects participating in clinical research. Various ethical codes, federal and state 
regulations and professional guidelines have been established that explicity outline what 
information must be provided to human subjects to insure that their participation is 
informed as well as volimtary (Piper. 1994, Cassidy & Oddi, 1986).
Informed consent is a concept developed from the moral principal of self- 
determination or autonomy ( Roach 1990). “ Autonomy means that persons have the right 
to determine their course of action on the basis of a plan that they have developed for 
themselves” (Davis, 1989, p.448). Additionally those patients who acquire more 
information are able to make better decisions (Beisecker & Beisecker, 1990). “Despite 
the fact that many individuals express a desire for more information and involvement in 
the health care process, it remains to be seen if they have adopted a more participative 
approach by becoming involved in decisions made about their health” (Brashers, Haas &
A. t .  ^  ^  *  / *  «M A X / ^  k» W AM & AAWW «AAA *  S X A W A A V  M iA W  r v  X /A  «A X /A Xr X V
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actively participate in health care decision making ( Brashers, Haas & Neidig, 1999; 
Beisecker & Beisecker, 1990; Hinckly, Craig & Anderson, 1989).
There are several ways to obtain a subject's consent, but almost all o f them 
involve written documentation (Federal Regulations Governing Human Experimentation, 
46.117(a), so the most common method of obtaining informed consent is through the use 
of written consent forms. However, questions recently have been raised as to whether or 
not this method guarantees that research subjects are making airtonomous, informed 
decisions (Tenthorey, & Dison, 1996; Marwick, 1998; Energy Times, February, 2000).
Problem
A recent article indicated that research subjects typically read less than fifty 
percent of a written consent form ( New York Times, May 1999). There are several 
results from this: Subjects are not truly knowledgeable about the study they are agreeing 
to participate in, dissatisfaction with the consent process, lawsuits by clinical research 
subjects (Kaplan & Brownlee, 1999; Las Vegas Review-Joumal, December 9,1999), and 
in extreme cases even injury or death (Las Vegas Review-Joumal, May 24,2000).
Sieitificance
The need for the protection of human subjects involved in research was brought 
to the world’s attention after World War H, during the Nuremberg trials. The first effort 
to establish formal ethical standards for human subjects research is known as the 
Nuremberg Code (Iserson, 1999). Nearly every major ethical code or guideline for
h u m a n  r e w a r r h  H ew ln n m t c tn rp  th e  N irre m h ero  tr ia lc  h a c  h e e n  ha«*rf a t le ac t in  n a r t  n n
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the Nuremberg principles. It is only in the last 20 years that most o f these codes and 
guidelines have been enacted (Grundner, 1986).
Despite the existence o f regulations, codes, and guidelines, abuses in human 
research continue to take place. In 1963 twenty-two subjects were injected with live 
cancer cells without being informed at the Jewish Chronic Disease Hospital in New York 
(Grundener, 1986). An audit by the Food and Drug Administration of studies conducted 
between 1977 and 1983 revealed that more than 10 percent of clinical drug studies had 
deficiencies in one or more o f the following areas: subjects’consent, accountability' for 
drugs, adherence to research protocol, and accuracy or availability of protocols for the 
study (Hammerscfamidt, 1992). Recently the problems with patients rights have resulted 
in the closure of studies at well-respected universities: Duke and the University of 
Pennsylvania (Kaplans & Brownlee, 1999; “FDA: Teen too sick”, 1999).
One of the methods developed to protect the rights of research subjects is the 
informed consent document The goal of this document is to provide potential research 
subjects with all the information they need to make an informed autonomous decision 
about participating in a research trial.
Nurses working in the field of clinical research often have the responsibility of 
administering the informed consent document and insuring that potential research 
participants understand the information in the consent prior to signing i t  The problem is 
that even with encouragement potential subjects do not always read the entire clinical 
drue trial consent form.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4Purpose
The purpose of this study was to identify how much of the consent form clinical 
research subjects read when they agree to participate in clinical drug studies. An 
additional goal of this study was to learn more about why research subjects read or do not 
read all of a consent form.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2
REVIEW OF RELEVANT LITERATURE 
Introduction
A review of the relevant literature covering clinical drug studies was conducted to 
identify which variables were most likely to have an influence on the amount of the 
informed consent that was read. A brief historical overview of the development of 
informed consent in clinical drug trials is presented first to give the reader background 
on informed consent and protection of subjects rights.
Historical Overview
The Federal government regulates clinical research involving human subjects by 
enacting a statute (law) and then delegating to a government agency the responsibility to 
define and enact the law by issuance of regulations ( Wing, 1985). These regulations, 
authorized by statute, are published (Annas et al., 1981) and implemented under statutory 
law. Such regulations are part of that law and violation of the regulation is a violation of 
the law (Wing, 1985).
In the United States federal regulation o f research was originally  done by the 
Department of Health, Education and Welfare ( now the Department of Health and 
Human ServicesDEHS). Its actions and authority are in accordance with its powers 
under the Public Health Act to regulate the research fcr which it pro vides funds. The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6Federal Drug Administratioa and the Public Health Service (PHS) are agencies of the 
DHHS whose regulations are now the standard for protecting human subjects in the 
United States (Veatch, 1987). These regulations go beyond the standards set by the 
Nuremberg Code and the Declaration o f Helsinki, specifically regarding the requirement 
that all investigations be reviewed by an independent committee prior to being started. In 
addition, the FDA establishes standards for the research protocols that it will accept as 
evidence of the safety and efficacy of drugs (Hershey & Miller, 1976).
The Food and Drug Administration (FDA) is the agency responsible for consumer 
protection in the use of cosmetics, foods, and drugs, and was the first agency in the 
DHHS to regulate clinical investigations. The first congressional policy on informed 
consent was the Drug Amendment Act of 1962 that came into being after the 
Thalidomide disasters (Oddi & Cassidy, 1998). The Kefauver-Harris amendments of 
1962 required that informed consent be obtained fi'om potential human subjects prior to 
their participation in the testing of investigational drugs. These amendments were 
limited though because the FDA did not want to interfere with doctor-patient relations 
and waived consent if the doctor did not believe it was in the patient’s best interest to 
know he/she was in a study, or if it was not feasible to gain informed consent from 
subjects (ACHRE Report p.l). Formal department policies were published in 1967, and 
additional regulations were added in 1971 ( Hersey & Miller, 1976) that covered 
potential subjects rights.
In 1974, Title El of the National Research Act was signed into law. This act 
established a National Commission for the Protection o f Human Subjects of Biomedical
■ ■ ■ » « ■ ^  > ÉÉÉXrkI» X M A V  A A A M ^X V  '  ^  .  « « « ** *-*'
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7concerning human subjects involved in research sponsored by the federal government 
(Veatch, 1987). Proposals by this commission were part of the 1981 regulations 
published by the DHHS. This commission also identified three moral principles, known 
as the Belmont principles, as the framework for guiding the ethics of research involving 
human subjects. The Belmont principles are respect for persons, beneficence, and 
justice. The commission was required to examine the “nature and definition” of 
informed consent and argued that the basic justification for the obligation to obtain 
consent is the moral principle o f respect for persons (ACHRE chapt 3).
In 1995 President Clinton established the National Bioethics Advisory 
Commission (NBAC) to review how human subjects rights were protected. The Office 
for Protection from Research Risks (OPRR) is within the National Institute of Health 
which funds much of the research that OPRR oversees. OPRR was criticized by the 
NBAC for its lack of ability to carry out investigations (Marwick, 1998).
In addition to federal standards, professional organizations have established 
guidelines for clinical and other research. One organization, The American Nurses’s 
Association, has developed standards for nurses conducting research which includes the 
“Code for Nurses With Interpretive Statements” and the “ANA’s Human Rights 
Guidelines for Nurses in Clinical and Other Research” (ANA Guidelines on Ethical 
Values, Nursing Research 1968).
Some states have also developed regulations governing human research, but state 
regulations tend to focus on specific issues rather than broad areas. California statutes 
are found in the California Penal Code, 1977, and the California Health and Safety Code
1 0 7 8  M pw  V nrlf h ac  P iihH r H e a lth  I  a w e  ntiKHchaH in  10 7 ^  rn n ra m in c r  h tim an  r a c f a r r h
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8One thing that federal laws, state laws and professional guidelines have in common, is 
that they all emphasize that research can be conducted only after informed consent is 
obtained, which is the “autonomous authorization by individuals of a medical 
intervention or of involvement in research” (Beaucham & Childress, p. 143 1994).
The specific federal laws that govern informed consent are found in the Code of 
Federal Regulations, Title 21, parts 50,56, and 312, revised April 1,1998. Part 50, 
Subpart A defines the scope, what or who the regulations apply to and also gives 
definitions. Subpart B deals specifically with the informed consent by human subjects, 
general requirements for informed consent, exception from general requirements, 
exception from informed consent requirements for emergency research, elements of 
informed consent, and documentation o f informed consent Subpart B, 50.20 states that 
“no investigator may involve a human being as a subject in research covered by these 
regulations unless the investigator has obtained the legally effective informed consent of 
the subject or the subject’s legally authorized representative”. Additionally “ the 
information given to the subject or the representative shall be in language understandable 
to the subject or the representative”. Subpart B, 50.27 states that except in certain cases 
outlined in 56.109, informed consent shall be documented by the use of a written consent 
form, and either the subject or the subject’s representative shall have adequate 
opportunity to read the consent form before it is signed.
The above provisions are pertinent to this paper because they specifically outline 
what written information must be given to a potential research subject and how it should 
be given. The problem remains, however, that even if adequate information is provided,
S A W  A&W X  AWX&W  W A  SA A A W VAkJXM AASA XAAW « « « « « » «  S - 1 1 I I  lA W V  g X  W  I X iX W  1 1 X 1 .V 1 1 X 1 V X X
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consent. The next sections discuss Actors that have been found to impact 
comprehension of what people read.
Comprehension Factors
Informed consent forms are used to convey information to potential research 
subjects so they can reach a decision about whether they should participate. Department 
of Health and Human Services Regulations for the Protection of Human Subjects require 
that study information be presented at a level that is easily understood by the subjects 
who will be reading it (Tamowski, Allen, Mayhall and Kelly 1990). The next sections 
offer factors that have been identified as affecting reading comprehension and have 
potential to prevent or impede a potential subject from reading an informed consent 
document and understanding its content.
Readability
Readability is the reading grade level required to understand any given document 
(Grundner, 1986) and may influence how much of a consent form is read. Spadero 
(1983) foimd comprehension tests showed that about 50% of patients in general were not 
able to read, or had difficulty reading instructional materials written at the fifth grade 
level or greater. The study findings were that readability of the written patient material 
showed most to be above the eight grade level. Goldstein, Fraiser and Curtis (1996) 
reviewed 284 consent forms for clinical research and he found that the average form was 
written at a twelfth grade level, with less than ten percent written at the tenth grade level 
or below. Another study using the Gunning Fog Index and Flesch-Kincaid Formulas for 
readability fi^und that 100^ *» o f the 137 cori.^nt n,# în^ r;7y^rvh studies analyzed were
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written at grade level 11.1 to 14.1 (Grossman, Piantadosi and Covahey 1994).
Seventy-one consent forms selected from research proposals on IRB agendas had 
grade level fifteen as the norm, and of sixty-four proposals approved only eleven had 
improved readability as recommended (Hammerschmidt, 1992).
Studies by Lawson and Adamson (1995), LoVerde, Prochazka and Byyny (1989), 
Morrow (1980) and Murgatroyd (1991) reached similar conclusions as the before 
mentioned studies, that the readability of informed consent material was at a grade level 
higher than that attained by the average research subject. Only two studies found no or 
only slight problems with readability. An attitudinal survey of 45 oral surgeons in 
Canada found that only 63% percent of their patients could both read and understand 
consent forms used by the surgeon (Freedman & Dunn, 1984).
An additional problem with readability is that self-reported educational status 
may not accurately reflect actual reading ability. Even when patients correctly report last 
grade completed in school this does not indicate actual reading ability (Davis e t  al.,
1991, Davis, Long, Jackson, Mayeaus 1993). Patients in studies by Davis, Doak, Jacson 
and Gault read four to five grade levels below the last grade they attended ( Murphy, 
Cavis, Long, Jackson, Decker 1993).
The importance of readability is that written informed consent documents are 
used to covey specific study information. If the information is not at a level that is easily 
understood by the potential subjects he/she may not be able to arrive at an informed 
decision concerning their willingness to participate.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Format
A second variable that may influence how much of the consent form is read is the 
format Format refers to the way the consent is arranged and can include type size, order, 
spacing, font and style. Taub, Kline, and Baker (1981) discussed size of typeface as a 
potential problem for older volunteers. A later smdy by Taub and Sturr (1990) again 
identified format problems with older subjects due to vision problems. Length of the 
form has also been found to affect reading in a study of patients in chemotherapy trials 
when 75 women were tested for their preferences for short, medium, or long consent 
forms. Most patients preferred long forms with more information but those receiving the 
long forms had the most difflculty answering basic questions about the study (White, 
Muss & Micheiutte, 1984).
Another area identified by Cardinal, Martin and Sachs (1996) was that most 
forms were not “user-fiiendly”. That is they do not use formats such as double spacing 
and large type size. Epstein and Lasagna (1996) gave consent forms of different lengths 
to 66 subjects, and concluded that comprehension and retention was greatest when the 
information was clearly and briefly stated.
A study by Peterson, Clancy, and Champion (1992) used computer programs to 
improve the readability of consent forms. The computer corrections gave little 
improvement in readability scores but evaluations by volunteers rated the graphically 
improved versions as easiest to comprehend.
The importance of format is similar to the importance of readability. If  the 
consent form is a written document and because of print size or other problems with 
format the inform ation is  not easily understood it can interfèr w ith notential research
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
12
subjects understanding the information they need to make an informed decision. 
Comprehension
Comprehension is the measure of the understanding of the information potential 
subjects have received A review of the literature on comprehension of informed consent 
documents confirmed that research subjects do not have enough understanding of what 
they read to make informed decisions. Miller, Searight and Grable (1994) conducted a 
study of 168 patients enrolled in a clinical trial. A telephone survey was used to evaluate 
recall of study information from the informed consent Most patients rated themselves as 
well-informed about the study but were not able to recall important study information.
Fifty' patients participating in twenty-three different research protocols were 
evaluated for understanding of the consent forms and only one-half were rated as 
adequately informed (Schultz, Pardee & Ensinck 1999). A smdy, conducted in Veterans 
Administration hospitals involving 156 research patients, revealed that of 40 consent 
forms analyzed, a college-level education on the average was required for adequate 
comprehension (Riecken & Ravich, 1982). McCormack, Evoy and Mulcahy (1997) 
tested 50 patients who had consented to orthopedic procedures during their post­
operative stays. Most of the patients showed limited understanding of the terminology 
used in the consent forms they had signed, indicating they may have consented to 
procedures they did not really understand. Waggoner and Mayo, (1995) and Waggoner 
and Sherman (1996) conducted smdies to evaluate the understanding of 25 commonly 
used words in clinical research consent forms. The first smdy involved 287 subjects, the 
second 302 subjects. In both smdies, understanding o f  the words was highly variable 
with those silhiects who had higher eritirationc dnino hptter nuerall
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Problems with readability and format can prevent potential research subjects from 
receiving important study information. Research on comprehension is important since it 
has been shown that readability as the sole measure of patients’ comprehension of 
medical consent forms is not a sufficient measure of potential research subjects ability to 
understand the information that is provided in the informed consent process (Mariner & 
McArdle, 1985).
Subject Satisfaction
The literature also suggests a relationship between satisfaction with the research 
study and the participant’s knowledge of the study. Research concerning subject 
satisfaction with the consent process was found in only three studies. Tabak (1995) 
interviewed 66 patients, most stated they did not have sufficient time to decide if  they 
wanted to participate, and a small majority responded they felt pressured to consent. 
Verheggen, Jonkers and Kok (1996) interviewed 198 patients involved in clinical trails in 
the Netherlands. Overall the patients reported being satisfied with both oral and written 
consent procedures. Williams, French and White (1997) surveyed fifty-nine patients who 
were asked to participate in a clinical trial and they stated they were satisfied with their 
decision to participate.
Consent Process
Another variable that may influence how much of the consent form is read is the 
process, specifically how the form is presented to a potential subject. Morrow, Gootnick 
and Schmale (1978) did not determine how much of the form 77 subjects read, but did 
report a higher comprehension in patients who took the form home to read prior to
XX/xewxnr ma
XkW A W W A A X A A A ^ .  AAA W X /A A X A ftW X  X W  XAAW A ^ A X /A A X / W y  W V  XXA AAAAXAAAAg«3* A A X/ X A A A A V A V A A W  rV C A O  A VXAAAXA a h
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14
comprehension scores or level of satisfaction between two groups of out-patients who 
either received a consent form 24 hours before the procedure and those who received it 
immediately before the out-patient procedure (Neptune & Hopper 1996).
Patient Advocacv
A final factor that may influence the amount of the consent form that is read by 
potential clinical research subjects is their degree of patient advocacy. Stress caused by 
chronic or life-threatening illnesses can cause a “self-help” response (Brader, 1990) in 
which patients are more likely to become “activists” or active agents (Thouts, 1994) in 
managing their illness. Brashers and Klingle (1992) maintain that activists are more 
involved in decisions about their health care. This involvement can be described as self- 
advocacy. Self-advocacy behaviors are used to represent “one’s own interest in decision­
making processes” and can result in a change in physician-patient interactions (Brashers, 
Haas & Neidig, p. 99,1999).
Ballard-Reisch (1990) suggested a model of physician-patient interaction that 
would be different fixjm the traditional encounter where the physician has the power over 
the patient She purposed that physicians and patients share responsibilities for decisions 
using open communication. Beisecker and Beisecker (1993) see this change in 
communication style between physician and patient as a shift from a paternalistic to a 
consumeristic model o f interaction. They also suggested that individuals following the 
consumeiistic model desire more information from their health care provider.
Related to self-advocacy is the level of desire to participate in medical decision
making by patients. Strull, Lo, and Charles (1984), assessed patient’s preferences for
^ 1
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than half of the patients requested more information about their disease. In this smdy it 
was determined that clinicians overestimated their patients desire to be involved in 
therapeutic decisions.
Robinson (1986) analyzed taped informed consent discussions with 644 patients 
prior to cardiac surgery. Twenty-five percent of the patients refused to hear part or all of 
the informed consent information. Beisecker and Beisecker, (1990), Thompson, (1994), 
and Waitzkin (1985) question whether patients are taking a more participative approach 
in decision making about their health despite the fact that patients express a desire for 
more infbrmatiotL Research by Hinckley, Craig and Anderson (1989) indicates that in 
actual practice the majority of patients are not willing or able to take an active role in 
health care decision making. Of the patients who do desire more information about 
health care and participate more in the decision-making process about care Beisecker and 
Beisecker (1993) saw a switch by these patients firom a paternalistic to a consumeristic 
model of decision making. Braden (1990), described a “self-help” response to chronic or 
life-threatening illnesses where patients were more likely to become “active agents” 
related to their illness. Even though it is recommended that patients should become more 
involved in health care decisions little research has been done to determine if patients are 
or desire to be more active (Brashers & Klingle, 1992).
Summary
The extensive literature search of Medline, Cinahl and government Internet sites 
found only a small number of studies addressing how much of the informed consent 
document is actually read by clinical research subjects. O f the studies that were found it
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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can. be concluded that research subjects have limited understanding and comprehension 
of the study they are agreeing to participate in if they do not read the informed consent 
document This also means they can not give true “informed” consent to participate. 
These findings are supportive of a need for further study to better understand why 
research subjects do or do not read consent material and how it may affect subject 
satisfaction with the study as well as impacting study data.
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CHAPTERS
FRAMEWORK
This chapter presents the theoretical framework used in this study, research 
questions, theoretical definitions, operational definitions and assumptions.
During the review of literature variables were identified that might influence how 
much of the informed consent document is read by potential research subjects. The type 
of relationship potential research subjects have with their health care providers has been 
suggested as one of the variables that influence how much of the consent form is read. 
Asymmetric or paternalistic interactions where the health care provider has the majority 
of influence in the encounter is usually the most common type of interaction (Guttman, 
1993; Treichler, Frankel, Kramerae, Zoppi, & Beckman, 1984). However the relationship 
can vary between the extremes of paternalism and consumerism (Gadow 1983).
The Existential Advocacy model proposed by Gadow (1983) was chosen as the 
framework for this study because it stresses the principle of self-determination in patient 
health care decisions while allowing for a variety of interaction types. Gadow proposes 
that in “ any given encounter the patient and nurse can freely decide whether their 
relationship shall be that of child-and-patient, client-and-counselor, friend-and-fiiend, 
coUeague-and-coUeague, and so on through the range of possibilities” (p. 42). The type 
of relationship may determine how much information the potential subject wants to
icucivc.
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Theoretical Framework 
Gadow defines existential advocacy as '^ e  nurse’s assistance to individuals in 
exercising their right o f self-detennination, through decisions which express the full and 
unique complexity of their values” (1983, p.55). Informed consent can be defined as the 
consent of an individual or his or legally authorized representative to participate in 
research without undue inducements or any form of fraud, deceit duress, or other 
constraint or coercion (Southwick, 1988; Bok, S. 1992). Government regulations 
mandate what information must be presented to the potential research subject to enable 
them to give informed consent. Legal obligations can be met by giving information to 
potential research subjects in the form of a written document (Code of Federal 
regulations. Title 21). However, the review of literature has identified several variables 
that can interfere with potential subjects receiving the information that they need to make 
a truly informed consent. Gadow recognizes that there are a variety of interaction types 
between health care providers and patients because each patient has “unique strengths 
and complexity” (1983 p. 43).
Gadow states that the concept of existential advocacy is the “opposite of 
paternalism”. She defines paternalistic acts as those which “limit the rights of 
individuals in their own interests”(p.43). Another view of paternalism is that it is 
sometimes better for the patient if  the person who makes the decisions is the one who is 
most knowledgeable in the situation. The intent of informed consent is not met during a 
paternalistic type interaction.
Although advocacy is opposite from paternalism it is not consumerism. Gadow
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with “technical” assistance only, where information is given but no recommendations are 
provided. Existential Advocacy’s goal is to “help persons become clear about what they 
want to do” by being interested in the other’s good more than their own (Gadow p.44- 
45).
The object of this study was to determine if subjects made informed consent 
decisions to participate in clinical drug studies based on how much of the consent form 
they read and their level o f self-advocacy. According to Gadow’s self-advocacy 
framework the potential subject has varying needs at any given time concerning the 
amount of help needed for informed decision making.
Research Questions 
Research questions for this study were developed from Gadow’s theory of 
Existential Advocacy (1983) and findings from the literature review.
1. How much of the written consent form do clinical research subjects read?
2. What is the relationship between how much of the consent form clinical 
research subjects read and self-advocacy?
3. What is the relationship between how much clinical research subjects read 
and the variables of sex, age, ethic group, gender, marital status, educational status and 
occupation?
4. What reasons do clinical research subjects give for reading or not reading 
the informed consent document?
5. Do clinical research subjects who read all or nearly all of the consent form
have different reasons for participating in clinical research trials than those who indicate
tKat ncttycant
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Definitions
Informed consent is the intentional autonomous authorization, with substantial 
understanding and lack of substantial control by others (Beauchamp & Childress,1994). 
Informed consent was operationalized in the clinical drug studies as the process of 
receiving, reading, and signing the study information (Beauchamp & Childress, 1994). It 
was fulfilled if  a research subject received a consent document that had been approved by 
an institutional review board after fulfilling all government and or local regulations. A 
wimessed signature on the informed consent was necessary, but no requirement to verify 
that the consent was read, or was understood.
Existential advocacv is a process that involves the nurse and the patient deciding 
what the relationship will be in health care encounters (Gadow, 1983). The patient and 
health care provider’s relationship can vary from paternalism to consumerism (Brashers, 
Haas &Neidig, 1999). Existential advocacy was operationalized by the summed score 
from the participants responses on the Patient Self-Advocacy Scale which measured the 
level of self-advocacy on a continuum from paternalism (not an advocate) to 
consumerism (active self-advocacy).
Clinical research subject is an individual participating, or who has participated in 
a  pharmaceutical drug study.
Readabilitv is the reading grade level required to understand an informed consent 
document.
Format is the way the consent form is arranged including type size, order, 
spacing, font and style, measured by question two in the demographic data form.
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consent document, measured by question three in the demographic data form.
Subject satisfaction is whether or not clinical research subjects received the 
amount o f information about a study that they desired, measured by question seven on 
the demographic data fonn.
Assumptions
Study participants will honestly answer questions regarding how much of the 
consent form they read and why or why not
Summarv
Existential Advocacy was chosen as the framework for this research study 
because it stresses the principle of self-determination in patient health care decisions. 
Research subjects have the right to know what they are getting into and the right to say 
no for good reasons, bad reasons or no reason and the consent process has been 
developed to insure that this right to make an independent decision is honored.
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CHAPTER 4 
METHODOLOGY
This chapter describes how the study was conducted. The subsections covered 
include study design, population, sample, setting, procedure, tools, statistics, and human 
subject rights.
Design
A comparative descriptive design that examines and describes “differences in 
variables in two or more groups that occur naturally in a setting”, was used (Bums & 
Grove, 1997). The design was used to examine and describe differences in variables 
between those subjects who read all of the consent form and those who did not read all of 
the consent form.
Population
The target population was any person age 50 to 75, who signed an informed 
consent document and agreed to participate in a clinical research trial for a 
pharmaceutical company. Excluded groups were vulnerable populations, cancer and HIV 
trial participants. The accessible population was people who had signed an informed 
consent document within the previous year and agreed to participate in a clinical research
22
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trial, were still participating in the research trial and were being seen at one of the three 
research centers where data were collected.
Sampling
Convenience sampling was used to identify the first one hundred usable responses 
by people in the before mentioned groups who volunteered to be part of this study.
Setting
The sample was obtained from three privately owned for profit research centers 
located in Ohio and Nevada. The three sites were similar in size, subject population, had 
a single investigator and two research coordinators. Persons asked to participate in this 
research study were subjects enrolled in the same clinical drug trials and who had the 
same informed consent documents.
Procedure
Research subjects who where currently taking part in a clinical drug trial were 
approached after all visit procedures were completed when they came to one of the 
centers for their regularly scheduled appointment The purpose of this study was 
explained to the subject by a research coordinator who was trained by the principal 
investigator. The same procedure was followed at each site. If the person expressed 
interest in participating in this study they were given a consent document to read. If the 
subject consented to participate they signed the informed consent. Next the subjects
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the demographic data form (DDF) and the second questionnaire was The Patient Self- 
Advocacy Scale (PSAS). After completing both items the subject was asked to place the 
questionnaires in a plain envelope and seal i t  The envelopes were stored in a locked 
cabinet until they were mailed or delivered to the principal investigator. After it was 
verified that the consent form had been signed the questionnaires were separated from the 
consents to maintain patient confidentiality. The data were transferred to a computer 
spread sheet The completed questionnaires and Patient Self-Advocacy Scales will be 
destroyed after a minimum of three years.
Tools
Data were collected using two tools. The first tool was the Demographic Data 
Form (DDF), found in appendix A. This form was developed by the researcher and 
reviewed by two expert nurses for clarity and conciseness after which modifications 
suggested by these nurses were made. The purpose of the DDF was to obtain basic 
demographic information about the sample such as age, marital status, educational level, 
and gender. These questions were identified as possible infiuencing factors based on the 
Strull (1984) study in which a correlation was found between degree of decision making 
and gender, age, race and education level. In addition to the previous questions subjects 
were also asked how much of the clinical trial consent form they had read and why.
Three hems, questions 3 ,4  and 5, dealt with the subjects’ subjective opinion of their 
comprehension of the consent form and possible variables that may have interfered with 
comprehensioiL Item 6 on the form asked for reasons the subjects had for participating
V lA W  V l A i X l V O k  V U U g  U A C U *
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The second tool used was the Patient Self-Advocacy Scale (PSAS), (Brashers, 
Haas & Neidig, 1999). Patient Self-Advocacy was identified as a possible variable 
influencing the amount of the clinical trial consent form subjects read. The PSAS was 
used to measure patient involvement in health care decision making and scores of 
possible low of 18 reflecting low self-advocacy or paternalism to a possible high of 90 
for self-advocacy (Brashers, Haas & Neidig 1999). The PSAS was developed because of 
some questions raised in a 1984 research study concerning shared decision making by 
patients and clinicians. Strull, Lo and Charles (1984), found that although shared 
decision making had been identified, little was actually known about how much decision 
making patients actually prefer. The PSAS was chosen as a tool because of the 
framework selected for this study, existential advocacy. Gadow (1983) states that at any 
given time the potential subject has varying needs concerning the amount o f help they 
want with health care decision making, an opinion shared by Ingelfinger (1980).
The Patient Self-Advocacy Scale is an 18 item questionnaire answered in a 5- 
point Likert format ( Brashers, Haas & Neidig 1999). To test the validity of the PSAS 
the authors used several other measures. Discriminent Validity was evaluated by the 
Desire for Control Scale (Burger, 1992), Health Opinion Survey Instrument (Krantz, 
Baum & Wideman 1980), Desire for Autonomy Scale (Ende, Kazis, Ash & Moskowitz 
1989), and Health Locus of Control Scale (Dahnke, Garlick & Kazoleas, 1994). A 
combined sample of 392 subjects was used to evaluate the tool, 174 adults from an HIV- 
AIDS population and 218 adults from a general population. Conclusions by Brashers, 
Haas, and Neidig (1999), were that “this was a reliable and valid means for measuring 
patient mVulvcmcnt in health care ucCiSiOü making and ihai measuring seir-advocacy is
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important because it may be associated with increased health care participation” (p. 113 ).
To assess efiBcacy of the measurement tools for this study a pilot study was 
conducted consisting of 5 individuals age 50 to 75 who had previously participated in a 
clinical drug study. They were asked to review the questionnaires and make suggestions 
regarding readability, comprehension and format. The pilot group requested changes in 
font size (larger), and terminology. Specifically they suggested referring to the studies 
they had participated in as “drug” studies. Changes were made to the questionnaires 
following their suggestions.
.Analvses
Nominal and ordinal data were collected for this smdy. Both descriptive and 
inferential statistics were used to analyze the data and because of the data collected 
nonparametric tests were used. The SPSS computer program used descriptive statistics 
including measures of central tendencv' and measures of distribution to describe the 
sample obtained.
Research question number one. How much of the written consent form do 
research subjects read? was answered by question one on the DDF. Research question 
two. What is the relationship between how much of the consent form clinical subjects 
read and self-advocacy? was answered by obtaining the PSAS total summed score of 
items and then looking for a relationship between PSAS scores and the amount of the 
informed consent that was read. Research question three. What is the relationship 
between how much clinical research subjects read and the variables o f gender, age, ethic 
group, marital status, educational status and cccupaticn? was answered by items 10
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through 15 on the DDF and item one on the DDF. Research question four. What reasons 
do clinical research subjects give for reading or not reading the informed consent 
document? was answered by the second part of question 1 and question 2 on the DDF. 
Research question 5, Do research subjects who read all or nearly all of the consent form 
have different reasons for participating in clinical research trials than those who indicate 
they read little or none of the consent form? was answered by question 6 on the DDF.
Human Subjects Rights 
Human subjects rights approval was obtained form the Department of Nursing 
and the Human Subjects Rights Committees at the University of Nevada, Las Vegas, (see 
Appendix A). Prior to participation in this study all subjects were given an informed 
consent document to read that explained the purpose of the study, potential risks, possible 
benefits, and that their participation was voluntary (Appendix B). Participants were told 
that they could withdraw at any time without penalty and without affecting their 
participation in the drug study. Subjects who agreed to participate received a signed 
copy of the consent document. No minors or vulnerable populations, including cancer 
patients, intellectually impaired, HIV positive, nursing home residents, or non-English 
speaking patients were included. .All data were kept in a locked cabinet, and only 
numbers were used on the questionnaires for identification. Data were accessible only to 
the study personnel. There was no direct benefit to the subjects of participation in this 
study, but the results may benefit future clinical research participants. No risks related to 
participation in the research study were identified, the risk-benefit ratio was neutral, and
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CHAPTERS
RESULTS
This chapter discusses the findings of this study. Included is a description of 
sample and setting, the data analysis procedures and the results obtained from these 
analyses.
Sample
The target population for this study was any person age 50 to 75 who had signed 
an informed consent document and agreed to participate in a clinical research trial for a 
pharmaceutical company. One hundred and five subjects at three research centers agreed 
to participate in the study and returned informed consents, demographic data sheets and 
Patient Self-Advocacy Scales. Sites one and two were located in Las Vegas, site number 
three was located in Ohio. Site number one had forty-two participants, site number two 
had twenty-two participants and site number three had thirty-seven participants. 
Participants at all three sites were reflective of the people recruited into the clinical 
research trials showing no significant differences demogr^hically in regards to age, 
gender, education, marital status, race or occupation. All three sites were conducting the 
same research studies in therapeutic areas for hypertension, arthritis, female incontinence 
and diabetes. Although all the subjects suffer from chronic conditions none were life- 
threatening at the time of the study. These clinical research trials were testing drugs that
uwk /wi. uwwix uy L&ic ruuu cuiu nLummidUtiuuu ouu wcic avououic uiuy
28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
29
to participants in clinical research trials. Consent forms for the clinical drug studies the 
subjects were participating in were evaluated using the Flesch Readability Formula 
(Grundner, 1986) and had readability scores ranging from grade 10.3 to grade 12.
Eight subjects were initially excluded from the study. Four subjects did not meet 
the inclusion criteria for age. Four subjects were excluded from the study due to 
incomplete questionnaires. After reviewing the data from the eight excluded subjects the 
four originally removed due to age were returned to the sample when it was determined 
that they were age 75 when they originally had entered into the clinical research studies 
giving a total of 101 participants.
Demographics
The characteristics of the sample population were obtained through the use of the 
Demographic Data Form. The ages ranged from 50 to 76 years, with a mean age of 62.90. 
Descriptive statistics were used to organize the data regarding, gender, marital status, 
educational status, occupation and ethnic group ( see Table 1). Of the total participants 
78 (77.2%) had never been in a clinical drug study before, 23 (22.8%) had previously 
been in a clinical drug study. A crosstabulation was done to determine if there was any 
difference between those vdio had been in a study before and those who had not in relation 
to the amount of consent read. The analysis showed that of the 78 who had not been in a 
study before 78.2% read all the consent, and of the 23 who had been in a study before 
73.0% read all the consent. The conclusion was that there was no difference between the 
two groups due to previous study participation in relation to the amount of the consent 
form that was read.
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Research Questions
Research Question Number One
How much of the written consent form do research subjects read? This question 
was answered with data from question one on the Demographic Data Form. Seventy-eight 
(77.2%) of the one hundred and one participants answered that they read all of the consent 
form. Nineteen (18.8%) of the participants said they read most of it (% to %), three 
(3.0%) responded that they read some (% to ‘A) and one (1.0%) read a little (%). No one 
responded that they read none of the consent form.
Research Question Number Two
What is the relationship between how much of the consent form clinical subjects 
read and self -advocacy? The relationship between how much of the consent was read and 
self-advocacy was answered by first obtaining the total summed score of the eighteen 
items on the Patient Self-Advocacy Scale (PSAS). Question number 2 also asked 
participates how much of the consent form they understood (see table 6). Brashers (1999) 
study showed that the PSAS was able to discriminate between self-reported activist and 
nonactivist participants. The possible scores on this form range from eighteen to ninety 
with a score of ninety representing the highest level of self-advocacy. The sample’s 
scores ranged from a low of 42 to a high of 82. The mean score was 62.67 (SD = 6.68). 
Because of the small number (4) of subjects who responded that they had read less than 
most of the consent form it was decided that data firom this question would be recoded to 
two groups. One group represented those who read all of the consent form and the other 
group was those participants who read less than all of the consent form. The seventy-
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and a standard deviation of 6.31. The twenty-three participants who read less than all of 
the consent form had a mean score of 61.57 with a standard deviation of 7.85 on the 
PSAS. Anova results for read versus not read on self-advocacy was F= 0.94, (df 28,72), 
P=.55 (see table 2).
This finding supports the position there is no relationship between PSAS scores 
and amount of informed consent read.
Research Question Three
What is the relationship between how much of the consent form clinical research 
subjects read and the variables of age, ethic group, gender, marital status, educational 
background and occupation ? As in the previous question participants response to how 
much of the consent form did you read was recoded to those who read all of the consent 
form and those who read less than all of the consent form. Crosstabulations were done 
comparing all the above variables and read all the consent form or did not read all the 
consent form. No significant differences were found regarding age, gender, ethnic group, 
marital status or educational background. The variable of occupation had six categories 
casino, clerical, construction, homemaker, professional and retired. Of the six only one 
category showed a significant difference, and that was construction where 75% did not 
read all of the consent while 25% did read all the consent, however, this group only had 
four members so it is not possible to conclude that construction workers in general do not 
read all of a consent form. The conclusion is that the amount of the consent form read by 
this sample was not related to the variables o f age, gender, marital status, occupation, 
ethnic group, or educational background. See table 3 for details.
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Research Question Four
What reasons do clinical research subjects give for reading or not reading the 
informed consent document? This group was recorded to those participants who read all 
the consent form or did not read all the consent form. This question was answered on the 
DDF as an optional part to question number one. Subjects were instructed to select one or 
more answers if they did not read the entire consent form. One subject who reported not 
reading the entire form did not answer this question so there is no data as to why her/she 
did not read the entire consent form. One subject who read the entire consent form 
answered yes to the choice that “someone in the research department explained the drug 
smdy to me so I ^ d n ’t think I needed to read the entire consent form”. Of the participants 
who did not read the entire consent form fifteen (652%) responded that “someone in the 
research department explained the drug smdy to me so 1 didn’t think I needed to read the 
entire consent form”. Four (17.4%) of the group who did not read all of the consent 
responded that “my doctor suggested I take part in the drug smdy and I trust his/her 
judgment so 1 didn’t read the entire consent form”. Two (8.7%) of the respondents who 
did not read the entire consent said “a fiiend or family member read the consent form and 
explained it to me so I didn’t read the entire form”. One (4.3%) participant responded, 
“got information from a source other than the consent form” and two (8.7%) responded,
“I wasn’t in the mood to read the entire drug smdy consent form”. Seven (30.4%) 
answered “other”, for the reason they did not read the entire consent form. Only three 
who answered other wrote in a reason for not reading the entire consent One fifty-four 
year old female wrote in that she did not read the part pertaining to females of 
childbearing age. A fi^'-tv/o year old male who answered that he read some of the
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consent (1/4 to 1/2) and that someone in the research department explained the drug study 
to him wrote in that he “read the first form completely”. It is not known what he was 
referring to as none of the studies these participants were in had more than one consent 
form. The last “other” wrote in “bad eyesight” and also answered that a fiiend or family 
member read the consent form and explained it to me so I didn’t  read the entire consent.
Based on the data collected the conclusion is that those who did not read the entire 
consent form got the information from another source, most often from someone in the 
research department.
Research Question Number Five
Do clinical research subjects who read all or nearly all of the consent form have 
different reasons for participating in clinical research trials than those who indicate that 
they read little or none of the consent form? Data to answer this question were obtained 
from question one on the DDF and question six on the DDF. Participants had the option 
of choosing more than one answer for the reason they entered a drug study. The data 
regarding the amount of consent form read were again collapsed into two groups, those 
who read all of the consent and those who did not read all of the consent.
Crosstabulations were done to determine if there was any significant difference in 
the reasons participants gave for agreeing to be in a drug study wiio read all the consent 
form and participants v6o did not read all the consent form. Of the 19 who responded the 
study gave them a chance to get medical care they could not afford 6 (31.6%) did not read 
the entire consent. Of the 17 who responded that they entered the study because it paid 
money 6 (35%) did not read the entire consent. O f the studies that the sample was drawn 
from only one study bad a patient stipend for participation. Of the forty-eight who
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responded they had tried every other treatment and it had not helped, 13 (27%) did not 
read all the consent form. The most frequent reason given for participating was that it 
was an opportunity to obtain medication not otherwise available 59 (58%). The answer 
“I’ve tried every other treatment or medicine and nothing else has helped was selected by 
48 (47.5%) of the participants. A crosstabulation showed 70.8% of the participants that 
choose the opportunity to obtain medicine also choose no other treatment or medicine has 
helped. Participants who entered the clinical studies for money or to obtain medical care 
were less likely to read the entire consent form than those who entered the studies for 
other reasons. See details in Table 3.
Additional information was obtained from the DDF. (Question number 2 and 4 
asked general information about the consent form relating to readability. The results are 
in Table 4. Question three on the DDF asked how much of the consent form did you 
understand. Table 5 summarizes how much the participants understood and how much of 
the consent they read. It should be noted that the amount of consent form understood was 
not validated with an actual check of the participants knowledge of the study.
Not all the subjects who participated in the study had the same consent form for 
their drug study. No data were collected regarding which form they read. There were a 
total of four different consents that were created by four different pharmaceutical 
companies. All the consents were similar in length and reading grade level 10 to 12. The 
general information in the consents was the same as mandated by FDA guidelines.
Of the total participants 78.3% percent o f those who did not read the entire 
consent and 89.7% o f those who did read all answered that they received all the 
information that they wanted fix)m the consent However. 73.9% of those who did not
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read all the consent, and 83.3 % of those who did read all the consent said they asked 
questions before they signed the consent form. Another question asked the participants if 
they would be in a drug study again. Of those who did not read the entire consent. 87% 
responded that they would be in another study, 8.7% might be in another study, and 4.3% 
would not be in another study. Of the participants who read the entire consent form 
74.4% would be in another study, 21.8% might be in another study, and 3.8% would not 
go in another study.
Summarv
The answer to research question one, how much of the written consent form do 
research subjects read, is that of the 101 participants 77.2% said they read all of i t  
Question number two, asked what is the relationship between how much of the consent 
form clinical research subjects read and scores on the PSAS (self-advocacy). In this 
sample there was no difference in PSAS scores whether the participant read all or less 
than all of the consent form. Question number three, what is the relationship between how 
much of the consent form is read and the variables of age, ethnic group, gender, marital 
status, educational background and occupation.? Only one variable showed a relationship, 
with those in construction reading less of the consent than those in other occupations or 
retired. However there were only 4 members in this group so it is not possible to 
generalize this finding to construction workers in general. What reasons do clinical 
research subjects give for reading or not reading all the consent form was research 
question number four. Since this was an optional items on the DOF not all participants 
responded.
Of those who did answer the most frequently chosen reason for not reading the 
entire consent was that they received information from someone in the research
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department, perhaps leading them to believe it was not necessary to read the consent. The 
final research question was did research subjects who read all of the consent form have 
different reasons for participating in the research study than those who did not read all the 
consent form. More than a third of those who were in a clinical research study because it 
paid money, or they received medical care they could not otherwise receive, did not read 
all o f the consent form.
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CHAPTER 6 
DISCUSSION
The purpose of this descriptive study was to answer questions related to the 
informed consent process in clinical drug studies, specifically how much of the informed 
consent document is read and variables related to how much is read. This chapter 
discusses the major findings in relation to the research questions, study framework and 
previous research. Limitations that were identified are discussed as well as implications 
for nursing and recommendations for further research.
Research Questions
How much of the written consent form do clinical research subjects read? Of the 
one hundred and one participants wiio responded to this question seventy-eight (772%) 
answered that they read all of the consent These results contradict previous reports that 
research subjects read less than fifty percent of a written consent (New York Times,May 
1999). This is also in contrast to the researcher’s personal observations that research 
subjects do not read all of the consent form and FDA audits of research sites from 1977 to 
1984 that cite the most violations of FDA regulations to be in the area of informed consent 
(www.fda.gov/cder). Possible explanations for these findings may be that the participants 
observed by the researcher were not typical, participants may pretend to read the consent 
form (Tenthory & Dixon, 1996) and that the FDA audits may reflect problems with the
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The answer to the second research question, what is the relationship between how 
much of the consent form clinical research subjects read and self-advocacy was that no 
relationship was found. There was no significant difference in self-advocacy scores 
whether the participant read all, most, or some o f the consent The mean PSAS was 62.67 
with a standard deviation of 6.68. Two of the participants with the lowest scores on the 
PSAS, 42 and 49 reported reading most of the consent form. The third participant who 
scored 51 on the PSAS reported reading all of the consent form. A possible explanation 
for this finding may be that research subjects as a group may be more assertive in regards 
to health care than individuals who do not participate in clinical research studies. In 
addition, this sample may not be representative of the average research subject. During 
the literature search no studies were found that addressed this issue, so this remains an 
area that needs further research.
The third research question asked, what is the relationship between how much 
clinical research subjects read and the variables of sex, age, ethic group, gender, marital 
status, educational status and occupation. Because of the small number of subjects who 
read less than most of the consent the four groups were collapsed into two groups, those 
who read all the consent and those who read less than all the consent No statistical 
differences were found regarding the above variables regardless of the amount of consent 
that was read. Additionally no statistical differences were found on PSAS scores, the 
amount of the consent that was understood or the reasons for participating in a clinical 
study regarding the variables of sex, age, ethic group, gender, marital status, educational 
status or occupatioiL A possible explanation for these findings may be the homogeneous
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nature of the participant sample. The majority of subjects were retired, married 
Caucasians, with some college education. About two-thirds were female.
Research question number four, what reasons do clinical research subjects give for 
reading or not reading the informed consent document? The results from this question are 
inconclusive possibly because of the way the question was asked on the demographic 
data form. It was an optional part to the question that asked how much of the consent was 
read. It said that if you did not read the entire consent form check all the answers that 
apply. Since 77.2% of the participants answered that they read all of the consent form 
limited data were obtained. However 652 % of those who answered that they did not read 
the entire consent said that the reason was because someone in the research department 
explained the drug study to them. This was actually only fifteen participants in the smdy, 
but is valid because all fifteen also said that they asked questions about the smdy before 
they signed the consent However, IRB’s give approval based on the written material not 
that the researcher will provide oral information to all of the potential research subjects 
reading the form. Of concern is the possibility that information will not be provided 
because o f a conflict of interest due to that fact that investigators in clinical drug smdies 
usually receive payment based on the number of subjects who agree to participate in a 
smdy.
Do clinical research subjects who read all or nearly all of the consent form have 
different reasons for participating in clinical research trials than those who indicate that 
they read little or none of the consent form was the final research questioiL Again the 
respondents were collapsed into two groups, those who read all the consent and those who 
read less than all the consent Slishtlv more than 30% of those who entered clinical trials
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for money or because they could not afford to get medical care elsewhere did not read the 
entire consent form. This finding is bothersome because they may in fact represent a 
vulnerable population, the poor or uninsured and may not be giving true informed consent 
A second group, those who have tried every other treatment or medication with no success 
and are now seeking medication that is not available except in clinical trials are also 
vulnerable. Although the majority of this group did respond that they read all o f the 
consent, is their desire for relief influencing their decision to participate to a point where 
they may be willing to take risks that another individual who felt they had other options 
might not take. Also, at risk subjects consent forms do not differ firom not at risk subjects 
in relation to IRB approvals.
Studv Framework
The framework for this study was existential advocacy. The goal of existential 
advocacy is to “help persons become clear about what they want to do” stressing self- 
determination in health care decisions (Gadow pp. 44-45). The PSAS was used to identify 
the participant’s degree of self-advocacy. The scores of this group on the PSAS reflect 
their high level of involvement in health care decision making. This sample showed their 
involvement by reading most or all of the consent form, and responding they understood 
most or all of the consent form and that they received all or most of the information they 
desired. Additionally, 812%  of the participants answered that they asked questions 
before signing the consent. Verheggen, Jonkers & Kok (1996) interviewed 198 patients in 
clinical trials and found that overall they were satisfied with informed consent. He found 
that this satis&ction was influenced by attitudes toward medical care, research and trust 
in their physicians. Of the participants in this study 49.5% answered that one o f the
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reasons they went into the study was because their doctor said it would be a good idea 
reflecting their trust in their physicians. If Gadow ( 1983) is correct this would be also be 
an example of the physician acting in the interest of the patient’s good. However it is 
unknown what the physician’s motivation is, it may be the patient’s best interest, or it may 
also benefit the physician if he is being paid for conducting the clinical trial. In addition, 
this study did not identify if the research subject was made aware of the latter fact 
Previous Research
The results of this study appear to contradict other previous research in addition to 
those studies dealing with the amount of consent foim read. In comprehension studies, 
Riecken and Ravich, (1982) and Miller, Searight and Grable, (1994) concluded that 
subjects do not have an adequate understanding of the informed consent documents yet 
62.4% of the participants in this study reported they understand all of the consent, while 
30.8% understood most of the consent, and 4.0% understood some of the consent form. A 
limitation with this study is that there was no objective test of participants understanding 
of the consent form information. Their response was a subjective opinion of what their 
level of understanding was.
Implications for Nursing
Evidence in case law documents show health care professionals are legally liable 
for adverse outcomes by patients who do not understand important health information 
(Brandes, Fumas, McCllan, Haywood, Oheme-Frempong, & Taylor-Watson, 1996).
Also, if  a nurse, in lieu o f a physician, explains a medical or surgical intervention to gain a 
patient’s informed consent they can be held to the same standard as court would hold a 
physician (Curran, 1982). The signature of a low health-literacy patient on a consent form
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may not indicate informed consent (Cassileth, Zupkis, Sutton-Smith & Morch, 1980).
The legal validity of the consent may be questionable even if  the patients have read the 
form if there is incomplete comprehension of the material (Powers, 1987). Patients with 
poor health literacy that prevents their comprehension of the informed consent may also 
have problems understanding and following instructions concerning the clinical study they 
are participating in leading to poor compliance with the study requirements ( Spandorfer, 
Karras, Hughes & C ^uto, 1995). In addition such may also limit their reporting of 
serious events that may have an impact on approval of the drug by the FDA. If serious 
events are not reported and approval is given open public use may result in injury or even 
death due to lack of fiill and accurate reporting in the clinical trial.
Limitations
This study was limited to three research sites that were extremely similar as far as 
patient population and method of obtaining informed consent The participants were for 
the most part patients of the physicians conducting the clinical drug study and had some 
type of patient/ health care provider relationship with the research staff. At these sites 
R.N's are consenting the patients and this may not be the norm for all research centers. 
Additionally this was not a diverse group in many areas such as age, race, education or 
occupation. There were problems identified with the DDF. Information was lost by 
making some answers dependent on the answer to the previous question. No general 
conclusions can be drawn fi'om this study.
No information was obtained as to what type of research study the participants 
were taking part in. For example some participants were in a hypertensive study where 
numerous alternative medications are available to the public. Therefore it was not
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
43
necessary for them to participate in a clinical study to obtain medication for their medical 
condition. However the females participating in the urge incontinence study did not have 
the same number of alternatives available as those in the hypertension study. There are 
no medications currently available that are comparable to the one that was being test in the 
clinical trial. These differences may cloud some of the data.
The PSAS, which was used to test patient self-advocacy, had not previously been 
used on clinical research subjects. Because of what appeared to be some contractions in 
responses to questions regarding why the participants went into the study and high scores 
on the PSAS (my doctor suggested 1 enter the study), it might be that the tool is not 
discriminating enough for this group.
Conclusions
The results from this study cannot be generalized to all clinical research subjects. 
Results would indicate that this sample which was mostly retired, married, female, 
Caucasians with some college read and understood most of the consent form. They 
thought the form was boring but they received all the information they wanted. This 
groups main motivation for entering a clinical study was to get medication that is not yet 
otherwise available, and they also though it might help other people. Additional reasons 
for participation that were frequently chosen were that it would be interesting, their doctor 
thought it would be a good idea, and no other treatments were working.
Recommendations for Further Research
Based on the overall findings in this study the following recommendations are
made.
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1. Check the participants understanding of the consent form by asking a few 
pertinent questions about the consent after it has been signed. For example ask the 
participant to name two potential drug side effects, how many visits will be required and 
who to contact in an emergency.
2. Obtain the sample from a more diverse number of sites, such as for profit, 
non-profit, university based and centers that obtain research subjects through 
advertisements only
3. Obtain the sample finm sites where the consent process is conducted by 
nurses and non-licensed research coordinators.
4. Obtain a more varied sample in regards to age, race, education and reason 
for participation such as patient payment.
5. Have the subjects take a health literacy test such as the Rapid Estimate of 
Adult Literacy in Medicine (REALM) which can identify patients with low reading levels 
in relation to health terminology ( Davis, Long, Jackson, Mayeaux, George, Murphy & 
Crouch 1993).
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Table 1 Participant Demographics ( N=1 Oil 
Age Range 50-76 Mean= 62.90
33
Gender Freauencv Percent
Male 37 36.6
Female 64 63.4
Marital Status Frequencv Percent
Single 15 14.9
Married 56 55.4
Divorced 12 11.9
Widowed 18 17.8
Highest Education Freauencv Percent
Less than high school 4 4.0
High school 24 23.8
Some college 43 42.6
College degree 16 15.8
Some graduate study 5 5.0
Graduate degree 4 4.0
Technical training 5 5.0
Ethnic Group Frequencv Percent
African 5 5.0
American Indian 4 4.0
Caucasian 87 86.1
Hispanic 3 3.0
Other 2 2.0
Occupation Frequencv Percent
Casino 3 3.0
Clerical 8 7.9
Construction 4 4.0
Homemaker 8 7.9
Professional 13 12.9
Retired 41 40.6
Sales 4 4.0
Service 3 3.0
Technicians 12 11.9
Other 5 5.0
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Table 2 ANOVA Results for Read vs. Not Read on Self-Advocacv
Sum of df Mean F Sig.
Squares Square
Between Groups 4.771 28 .170 .944 .553
Within Groups 12.991 72 .180
Total 17.762 100
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Table 3 Crosstabulations Between Variables of Age. Ethnic Group. Gender. Marital 
Status. Educational Background. Occupation and Amount of Consent Form Read
Occupation Did not read all of consent Read all of consent form
Casino
% within occupation
0 3
100%
Clerical 2 6
% within occupation 25% 75%
Construction 3 1
% within occupation 75% 25%
Homemaker 2 6
% within occupation 25% 75%
Professional 3 10
% within occupation 23.1% 76.9%
Retired 6 35
% within occupation 14.6% 85.4%
Gender Did not read all of consent Read all of consent form
Male 7 30
% within gender 18.9% 81.1%
Female 16 48
% within gender 25% 75%
Marital Status Did not read all of consent Read all of consent form
Single 4 11
% within marital status 26.7% 73J%
Married 14 42
% within marital status 25% 75%
Divorced 1 11
% within marital status 8.3% 91.7%
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Widowed 4
% within marital status 222%
14
77.8%
Education Did not read all of consent Read all of consent form
Less than High School 1 3
% within education 25% 75%
High School 9 15
% within education 37.5% 62.5%
Technical Training 1 4
% within education 20% 80%
Some College 8 35
% within education 18.6% 814%
College Degree 3 13
% within education 18.8% 81.3%
Some Graduate Study 1 4
% within education 20% 80%
Graduate Degree 0 4
% within education 0 100%
Ethnic Group Did not read all of consent Read all o f consent form
African American 1 4
% within ethnic group 20% 80%
American Indian 0 4
% within ethnic group 100%
Caucasian 20 67
% within ethnic group 23% 77%
Hispanic 1 2
% within ethnic group 333% 66.7%
Other 1 1
% within ethnic group 50% 509o
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
57
Table 4 Cosstabulations Between Participants Reasons for Agreeing to be in a Clinical 
Drug Study and How Much of the Informed Consent they Read
Reason for Participation Frequencv Did not read all consent Read all of Consent 
Gave me a chance to get 59 10(16.9%) 49(83.1%)
medication not available
I thought it might help
other people 58 13 (22.4%) 45(77.6%)
I thought it would be
interesting 57 13 (22.8%) 44 ( 77.2%)
My doctor said it would
be a good idea 50 9(18%) 41(82%)
I’ve tried every other
treatment nothing works 48 13(27%) 35(73%)
Family said it was a 29 7 (24%) 22 (76%)
good idea to enter study
Other reasons 22 7(32%) 15(68%)
Chance to get medical
care 19 6(32% ) 13(68%)
Study pays money 17 6 ( 35%) 11 ( 65%)
I did not want to go 
against my Dr. or nurses
recommendation 4 1 ( 25%) 3 (75%)
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Table 5 Crosstabulation Readability Questions About the Consent Form and Read or Did 
Not Read All of The Consent Form
Readability of Consent Form Did not read all Read all
The consent was too long 7 11
The type in the consent 
was difficult to read 3 0
Did not have enough time 
to read the entire consent 3 4
I felt rushed to read the 
consent form 2 2
The consent form was 
boring 10 20
The consent form was 
clear 17 61
I received all the 
information I wanted 18 70
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Table 6 Crosstabulation Between How Much of the Consent Form Did You Understand 
and How Much of the Consent Form Did You Read
Did Not Read All of Consent Read All of The Consent
Understood Some
(%tol6)
3.5% total sample
1% 3%
Understood Most
(>/2 to %)
33.5% total sample
10% 23.5%
Understood All 
63% total sample
12% 50.5%
23% 78%
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DATE; Sqjtember 26,2000
TO; Joanne Robinson
Nursing 
Ml'S 3018
FROM; >^,D r. William E. Schulze, D ire c to r^
L OfSce o f Sponsored Programs (xl357)
RE; Status o f Human Subject Protocol Entitled;
“Variables Related to How Much of the Informed Consent Document is Read by
Clinical Research Subjects”
OS? #50ls0900-089
This memorandum is ofEcial notification that the protocol for the project referenced above has 
been ^ jproved by the Office of Sponsored Programs. The approval is for a period o f one year 
fiom the date o f this notification and work on die project may proceed.
Should the use o f human subjects described in this protocol continue beyond a year fiom the 
date of this notification, it will be necessary to request an extension
If you have any questions or require assistance, please contact the Office of Sponsored Programs 
at 895-1357.
cc; OSP File
Office of SQonsoreo Progrôrrs 
aSOs Marv;arc Parxwav • Ecx 451037 • Las Veoas. 'Jsvzca 8Sl54-‘037 
!7Q2: SS5-t357 • P.AX (702 895-4242
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Investigator Joanne Robinson _________________
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After reviewing this proposal, the members o f the _Departraent ofNursing, Human 
Subjects Rights Review Committee has indicated below their approval/disapproval 
oroposal.
of this
Signature o f Committee Members Approve Disapprove
'Cut.
iX
— -
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October 25.2000
Joame Rotuuon. RN 
S40 R Rancho Dm cSoiie A 
Las Vegas. MV 89106-3820
RE Data Collection
DearMs. Rofaioson.
I lecetv-ed your leques to love HoliyRenoer. RM assstyoam daa collection for raur thesis tonards a 
master's degree m tnssmg. .^fiercaieiiiilT levtcnfiogyoitr request, the consent fiitin. and qaesttoioBiies 
sncpiiel I felt it reasonaUe that the resescfa be conducted at Ohio CImicai Research. LLC
If I can be of fuiiber assisiaticsjsiease contaa toe at (440) 684-8900.
Sinceteiy.
Terence Isakov. MD 
Pcinocnl Investigator
Cc î&IIv Renner. .RN
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SOUTHWEST MEDICAL ASSOCIATES, INC
Clinical Trials Department 
Stephen H. Nfiller, MJ). Principal hivesrigator 
2316 W. Charleston Blvd., Suite 280 
Las Vegas, NV 89102 
Phone: 702-877-8675 Fax: 702-821-1322
October:. 2000
Joanne Robinson
2316 West Charleston Blvd.
Suite 280
Las Vesas, Nevada 89102
Re: Data collection for Master s Thesis 
Dear Joanne:
You have tny permission to approach patients at this research site for the purpose of 
obtaining data for mur master’s thesis on imormed consent It is understood that all 
patients will be informed that their participation is voluntary and not related to their 
participation in the pharmaceuncal studies.
Sincerelv
Dr. Stephaî^. Miller. MD 
Prindoamvktiaator
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WILLUM S. 30SSAK. M J)-. LTD. 
3115 SOCTH E.UTEHX .WENCï 
U S VECAS. XEV.AD.*. S910M3ST
Teicpbene73l>U40
October 2.2000
Joanne Robinson 
2316 W. Charleston Blvd 
Suite 280
Las Vegas, N \' 89102
RE: Data collection for master’s thesis
Dear Ms. Robinson:
: have considered your request for permission to collect data for you .Master's thesis on 
variables relating to the amount of consent form read by clinical research subjects. You 
have my permission to approach patients at this site for the purpose of obtaining this data.
William S. Bossak, .\LD. 
Princinal mvestizator
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U M ¥
Research Subject Information and Consent Form
TITLE: Variables Related to How Much of the Informed Consent
Document Is Read By Clinical Research Subjects
INVESTIGATOR: Joanne Robinson RN, ESN 
Department of Nursing 
University ofNevada, Las Vegas
You are being invited to participate in a research study about informed consent in drug 
studies because you are currently taking part in a drug study. The following information 
describes the study and your role as a study participant The research nurse will answer 
any questions you have about this consent form and about the study. Please read the 
consent form careftilly and do not hesitate to ask questions about the information 
provided.
PURPOSE OF THE STUDY
The purpose of this study is to identiA- how much of the consent form clinical research 
subjects read when they agree to participate in a drug study .An additional goal of the 
study is to learn more about why research subjects read or do not read all of the consent 
form.
DESCRIPTION OF THE STUDY
•After you have completed your routine visit for the drug study you will be asked to 
complete two questionnaires It will take you approximately '/i to % hour to complete 
both. One of the questionnaires will ask questions about how much of the consent form 
you read for the drug study you are now participating im The second questionnaire will 
ask you about health care decision making. After you complete the questionnaire place 
them in the attached envelope, seal it and return it to the research nurse. Approximately 
100 subjects will be enrolled in this study.
POTENTIAL RISKS AND DISCOMFORTS
Risks are minimaL Participants may feel some discomfort answering some of the 
questions and have the option to stop at any time and not hand in the questionnaire
POSSIBLE BENEFITS
Information gained may be benencial to health professionals concerned with the 
protection of human subjea's rights in clinical research studies.
Deoartment of Nursing 
■iSOS MaryianO Pa.v.vay • Sox453013 • '_as Vegas. Nevaca 59:54-3015 
rrnoi aosjyaeft • ri.ooi
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PAYMENT FO R PARTICIPATION
You will not receive any compensatioE for participation in this study. 
CONFIDENTIALITY
Information from this study will be confidennal. Your name will appear on this consent 
form but not the questionnaires and the consent forms will be kept separate from all other 
study information and will be stored in a locked cabinet located in the researchers office 
and destroyed three years after the conclusion o f the study. Information from this study 
may be presented at meetings or in publications; however, your identity will not be 
disclosed in those presentations.
VOLUNTARY PARTICIPATIONAVITHDRAWAL
Your participation in this study is voluntary. You may decide not to participate or you 
may withdraw from the study at any time without penalty and without affecting your 
participation in the drug study.
QUESTIONS
If you have questions about this research or your participation in this study contact: 
Joanne Robinson, the Department o f Nursing, UNLV @ 702-895-3360. If you have 
questions about your rights as a research subject, you may contact: University o f Nevada 
Las Vegas, Office of Sponsored Programs @ 702-895-1357.
Do not sign this consent form unless you have had a chance to ask questions and have 
received satismctory answers to aU o f your questions
CONSENT
I have read and I understand the information in this consent form describing this study 
All my questions regarding the study and my participation in it have been answered to 
my satisfaction. I freely give my consent to participate in this study until I decide 
otherwise.
I understand that I will receive a copy of this signed and dated consent form for my 
records.
Subject Name (Primed)
Subjea Signature Date
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Demographic Daia Form 
By Joanne Robinson
Please indicate your answer to the following questions with an “X”. These 
questions ^ l y  to the clinical research s tu ^  you are participating in for a 
pharmaceutical company to test a new drug.
1. How much of the informed consent document for the drug study you are 
participating in now did you read before signing it?
( ) I did not read any of the consent form.
( ) I read a little o f it (1/4 or less)
( ) I read some of it (1/4 to 1/2)
( ) I read most of it (1/2 to 3/4)
( ) I read all of it
If you did not read the entire consent form check aU that apply.
( ) Someone in the research department explained, the drug smdy to me so 
I didn’t think I needed to read the entire consent form.
( ) My doctor suggested I take part in the drug study and I trust his/her 
judgment so I didn’t read the entire consent form.
( ) A fiiend or family member read the consent form and explained it to 
me so I didn’t  read the entire form.
( ) I got information about the research study from a source other than the 
consent form.
( ) I wasn’t in the mood to read the entire drug smdy consent form.
( ) Other_______________________________________________
2. Please answer Yes or ^  to the followmg statements about the consent 
form for the drug study you are participating m now.
( )Yes ( ) No The consent form was too long.
( )Yes ( ) No The type m the consent form was difficult to read.
( )Yes ( )N o I did not have e n o i^  time to read the entne consent.
( )Y'es ( )N o I felt rushed to read the consent form.
( )Y'es ( )N o The consent form was boring 
( )Yes ( )N o The consent form was clear.
( )Yes ( )N o I received all die information I wanted about the study.
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3. How mricàoftiie consent fimnfiirtbe drug study did you understand.
( ) None of it 
( )AIittleofit (1/4 or less)
( ) Some of it (1/4 to )
( ) Most of it (1/2 to %)
( )MofrL
4. Were there any pans ofthe drug study consent fmmtiiatwere vague or 
not clear?
OYes
( ) N o
If you answered v «  to the above question please chedcaO statements that 
apply.
( ) The cfflisent form had Windsor phrases that I did not understand.
( ) The consent form descnbedsiucfy procédures that I did not 
understand.
( ) Ididnothaveadiaacetoaskquestûmsaboutairytbingldidnot 
understand.
( ) I was embarrassed to ask questions.
5. Did you ask any questions about die drug study before you signed the 
consent form?
O Y es
( ) No
Please go to page 3
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6. Why did you agree to be in the drag study? Please check aU the reasons 
that apply.
( ) My doctor said it would be a good idea.
( ) My family th o u g h  was a good idea.
( ) It gave me a chmice get medication that is not available at 
pharmacies yet 
( ) The study pays money to me for participatioiL 
( ) I thought it m i ^  help other people.
( ) Fve tried every other treatment or medicme for my condition and 
nothing else has helped.
( ) This is a  chance to get medical care that I could not otherwise afford 
to pay for 
( ) I diought it would be mteresting
( ) I did not want to go against my doaor's or nurse’s recommendation to 
go into the drug study.
( ) I thought it would please my doctor or nurse.
( ) Other (fill in )__________________
7. How much of the information that you wanted about the drug study did 
you receive?
( ) None
( ) A little ofthemformation I wanted (1/4 or less)
( ) Some o f the information that I wanted (1/4 to ‘/:)
( ) Most of tiie information that I wanted (1/2 to %)
( ) All of the information that 1 wanted
8. I would participate in another drug study agam because of my satisfaction 
with this study.
( ) Yes 
( ) Maybe
( ) No
Please go to page 4
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9. Have you ever been in a drug study before?
( )  Yes 
( ) N o
10. My age is :___________________
11. Gender
( )Male 
( ) Female
12. My marital status is:
( ) Single 
( ) Married 
( ) Divorced 
( ) Widowed
( ) Other__________________________
13. The highest level of education I have completed is:
C ) Less than high school 
( ) High school 
( ) Some college 
( ) College degree 
( ) Some graduate smdy 
( ) Graduate degree 
( ) Technical training
14. Ethnic group
( ) Afiican-American 
( ) American Indian/Alaskan 
( ) Asian/Pacific Islander 
( ) Caucasian 
( ) Hispanic 
( ) Odier
Please go to page 5
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15. What is your occupation?
) Casino 
) Clerical 
) Construction 
) Homemaker, not employed
) Professional, e.g. architects, engineers, health professional, or teachers 
)Retned 
) Sales
) Service, e.g waitress, cook, janitor, hair dresser 
) Technicians, e.g. computer programmer, health technician 
)Otiier________________________________________
Thank You, you have completed this questionnaire
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Patient Self-Advocacy Scale 
By D. Brasher
The following questions ask about your feelings about your health care. For each 
of the following questions, please indicate your level of agreement with the 
statement by drding either Strongly agree. Agree, Neutral, Disagree or 
Strongly disagree.
1 .1 believe it is important for persons with an illness to learn as much as they can 
about the disease and treatments.
Strongly agree Agree Neutral Disagree Strongly disagree
2 .1 actively seek out information on my health.
Strongly agree Agree Neutral Disagree Strongly disagree
3 .1 am more educated about my health than most U.S. citizens.
Strongly agree Agree Neutral Disagree Strongly disagree
4 .1 have full knowledge of the health problems of people like me.
Strongly agree Agree Neutral Disagree Strongly disagree
5 .1 keep notes about my illness and treatment
Strongly agree Agree Neutral Disagree Strongly disagree
6 .1 research the latest treatments for my illness.
Strongly agree Agree Neutral Disagree Strongly disagree
7 . 1 don’t get what 1 need from my physician because I am not assertive enough. 
Strongly agree Agree Neutral Disagree Strongly disagree
8 .1 am more assertive about my health care needs than most U.S. citizens. 
Strongly agree Agree Neutral Disagree Strongly disagree
9.1 frequently make suggestions to my physician about my health care need. 
Strongly agree Agree Neutral Disagree Strongly disagree
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10 .1 frequently offer my doctor suggestions about my care and treatm ent
Strongly agree Agree Neutral Disagree Strongly disagree
11.1 ask a lot of questions of my doctor.
Strongly agree Agree Neutral Disagree Strongly disagree
12. If my physician prescribes something I don't understand or agree with, I 
question it
Strongly agree Agree Neutral Disagree Strongly disagree
13. Sometimes there are good reasons not to follow the advice of a  physician.
Strongly agree Agree Neutral Disagree Strongly disagree
14. If 1 am given a treatment by my physician that 1 don't agree with, I am likely 
not to take it
Strongly agree Agree Neutral Disagree Strongly disagree
1 5 .1 don’t always do what my physician or health care worker has asked me to 
do.
Strongly agree Agree Neutral Disagree Strongly disagree
16. Sometimes I think I have a better grasp of what I need medically than my 
doctor does.
Strongly agree Agree Neutral Disagree Strongly disagree
17. My doctor works for me. 1 would find another doctor if I weren’t  satisfied with 
my health care.
Strongly agree Agree Neutral Disagree Strongly disagree
1 8 .1 make my own decisions about what treatments I will or will not use, even if 
my doctor prescribes it
Strongly agree Agree Neutral Disagree Strongly disagree
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